Want to see HK:1312 full AI Analyst Report?
Top Page
Kontafarma China Holdings Ltd
(1312)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.03
▼(-3.33% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by deteriorating profitability (negative operating results and significantly wider net losses in 2025), with additional pressure from a weak technical trend (price below key moving averages and negative MACD). Improving cash generation and reduced leverage partially offset these risks, but valuation signals are limited by the negative P/E and missing dividend yield.
Positive Factors
High Gross Margins
Consistently high gross margins (49%–58%) indicate durable pricing power or a favorable product mix. This structural margin cushion helps absorb SG&A or cyclical pressure, supporting long-term cash generation and strategic flexibility even if operating profits lag.
Negative Factors
Negative Operating Profitability
Persistent negative EBIT/EBITDA and a ~-47% net margin in 2025 signal structural weakness in operating economics. If operating losses persist, they will erode equity and constrain reinvestment, making long-term recovery and sustainable profitability harder to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Consistently high gross margins (49%–58%) indicate durable pricing power or a favorable product mix. This structural margin cushion helps absorb SG&A or cyclical pressure, supporting long-term cash generation and strategic flexibility even if operating profits lag.
Read all positive factors
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$167.36M
Dividend YieldN/A
Average Volume (3M)9.95M
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth1.92%
EPS Growth-468.15%
CountryHK
Employees714
SectorHealthcare
Sector Strength45
IndustryConstruction Materials
Share Statistics
EPS (TTM)-0.08
Shares Outstanding5,588,572,000
10 Day Avg. Volume1,701,000
30 Day Avg. Volume9,954,100
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Company Description
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory...
How the Company Makes Money
null...
Kontafarma China Holdings Ltd Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
46
Neutral
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 914.71M | 897.52M | 809.11M | 894.06M | 803.27M |
| Gross Profit | 513.64M | 516.16M | 471.29M | 506.22M | 396.18M |
| EBITDA | -153.53M | -49.93M | 78.50M | 26.93M | 112.18M |
| Net Income | -427.85M | -75.54M | -28.84M | -41.55M | -15.05M |
Balance Sheet | |||||
| Total Assets | 1.07B | 1.59B | 1.73B | 2.12B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 66.06M | 90.58M | 87.66M | 142.59M | 183.96M |
| Total Debt | 203.68M | 297.19M | 333.82M | 590.72M | 728.95M |
| Total Liabilities | 588.92M | 625.90M | 665.39M | 964.16M | 1.22B |
| Stockholders Equity | 553.26M | 978.70M | 1.06B | 1.10B | 1.19B |
Cash Flow | |||||
| Free Cash Flow | 53.15M | 33.41M | 12.92M | -53.84M | -49.31M |
| Operating Cash Flow | 76.68M | 47.05M | 37.12M | -2.17M | 75.07M |
| Investing Cash Flow | 8.82M | -6.01M | 144.14M | 121.53M | 23.24M |
| Financing Cash Flow | -90.16M | -42.52M | -198.81M | -137.33M | -99.80M |
Kontafarma China Holdings Ltd Technical Analysis
Neutral
0.03
Price Trends
0.03
Positive
0.03
Positive
0.03
Negative
Market Momentum
<0.01
Negative
53.70
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1312.
Kontafarma China Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$37.74B | 12.49 | 7.54% | 2.65% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$64.26M | -1.21 | -8.97% | ― | 63.58% | -38.19% | |
48 Neutral | HK$33.33B | -9.37 | -2.95% | 3.30% | -2.13% | -279.50% | |
48 Neutral | HK$739.99M | 2.19 | 2.06% | ― | ― | ― | |
43 Neutral | HK$167.36M | -0.38 | -69.10% | ― | 1.92% | -468.15% | |
42 Neutral | HK$656.85M | -0.11 | 211.43% | ― | ― | ― |
* Healthcare Sector Average
HK:1312
Kontafarma China Holdings Ltd
0.03
>-0.01
-3.33%
HK:3323
China National Building Material Co
4.27
0.22
5.48%
HK:0868
Xinyi Glass Holdings
8.48
0.27
3.29%
HK:3300
China Glass Holdings Limited
0.38
0.03
10.29%
HK:1252
China Tianrui Group Cement Co., Ltd.
0.24
-0.07
-21.31%
HK:1847
YCIH Green High-Performance Concrete Co., Ltd. Class H
0.48
0.04
9.09%
Kontafarma China Holdings Ltd Corporate Events
Kontafarma China Announces Resignation of Non-Executive Director Huang Yu
Jun 30, 2026
Kontafarma China Holdings Ltd announced that non-executive director Huang Yu will resign from the board effective 30 June 2026 to pursue personal career development, with both the company and Huang emphasizing there is no disagreement or outstandi...
Kontafarma China Refreshes Board and Committee Structure
Jun 30, 2026
Kontafarma China Holdings Limited has announced the latest composition of its board of directors, effective 30 June 2026, confirming Wang Limin as chairman and president alongside executives Ge Shouwen and Guo Zixiu. Independent non-executive dire...
Kontafarma China Wins Strong Shareholder Backing at 2026 AGM
Jun 5, 2026
Kontafarma China Holdings Ltd reported that all resolutions put to shareholders at its 5 June 2026 annual general meeting were approved by wide margins, with about 95.85% of votes cast in favour. Shareholders endorsed the 2025 audited financial st...
Kontafarma China Issues Supplemental AGM Notice to Revise Director Re-Election
May 18, 2026
Kontafarma China Holdings has issued a supplemental notice for its annual general meeting, scheduled for 5 June 2026 in Hong Kong, to update shareholders on changes to one of the meeting’s resolutions. The company is now proposing the re-ele...
Kontafarma China Names New Chairman as Leadership Shifts at Board Level
May 8, 2026
Kontafarma China Holdings has announced the resignation of executive director, chairman and president Wang Feifei, who is also stepping down from chairing several key board committees, with the company stating there is no disagreement with the boa...
Kontafarma China reshapes board and committee structure to bolster governance
May 8, 2026
Kontafarma China Holdings has reshaped its board composition effective 8 May 2026, appointing Wang Limin as chairman and president, alongside executives Ge Shouwen as vice president and Guo Zixiu as financial controller, with support from one non-...
Kontafarma China Sets 2026 AGM, Seeks Fresh Share Issuance Mandate
Apr 23, 2026
Kontafarma China Holdings has called its annual general meeting for 5 June 2026 in Hong Kong, where shareholders will be asked to receive and adopt the audited financial statements for the year ended 31 December 2025. The agenda also includes re-e...
Kontafarma China Moves to Update Articles and Enable Treasury Shares Ahead of 2026 AGM
Apr 20, 2026
Kontafarma China Holdings plans to adopt a fourth amended and restated memorandum and articles of association to align its constitutional documents with updated Hong Kong legal and regulatory requirements on electronic dissemination of corporate c...
Kontafarma China announces board reshuffle with new executive director and vice president
Apr 16, 2026
Kontafarma China Holdings Ltd announced that executive director Liu Jiankun has resigned effective 16 April 2026 to pursue other work commitments, and will also step down from the company’s executive committee and share dealing committee. Th...
Kontafarma China Overhauls Board and Committee Structure
Apr 16, 2026
Kontafarma China Holdings Ltd has reshuffled its board structure with effect from 16 April 2026, confirming Wang Feifei as chairman and president alongside two other executive directors, one non-executive director and three independent non-executi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.